You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

head and neck cancer, docetaxel, pembrolizumab

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Boston, Massachusetts
  • +1 more
Feb 11, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +11 more
  • KEYTRUDA®
  • (no location specified)
Nov 17, 2023

Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8 Trial in Houston

Recruiting
  • Laryngeal Squamous Cell Carcinoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Advanced Cancer, Advanced Solid Tumor, Tumor Malignant Trial in United Kingdom (Fosifloxuridine Nafalbenamide, Leucovorin,

Not yet recruiting
  • Advanced Cancer
  • +16 more
  • Fosifloxuridine Nafalbenamide
  • +3 more
  • Birmingham, United Kingdom
  • +3 more
Feb 1, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Beijing, Beijing, China
    Beijing Tongren Hospital
Oct 26, 2023

Effect of Drug Trial in Sapporo (Docetaxel, Pembrolizumab)

Not yet recruiting
  • Effect of Drug
  • Sapporo, Hokkaido, Japan
    Hokkaido University Hospital
Feb 12, 2022

Head and Neck Squamous Cell Carcinoma Trial in Worldwide (Magrolimab, Pembrolizumab, Docetaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Chandler, Arizona
  • +59 more
Jan 20, 2023

Head Neck Cancer, Head and Neck Squamous Cell Carcinoma Trial (ALE.C04, Pembrolizumab)

Not yet recruiting
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Sep 19, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)

Not yet recruiting
  • Metastatic Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Portland, Oregon
    Providence Portland Medical Center
Jun 19, 2023

Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Malignant Solid Neoplasm
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Oligometastatic Squamous Cell Carcinoma of the Head and Neck Trial (Pembrolizumab, stereotattic ablation radiotherapy (SABR))

Not yet recruiting
  • Oligometastatic Squamous Cell Carcinoma of the Head and Neck
  • (no location specified)
Apr 14, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Head and Neck Squamous Cell Carcinoma Trial in Pittsburgh (Pembrolizumab, Cisplatin, IMRT)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 15, 2022

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Head Neck Cancer Trial in Baltimore, Chapel Hill, Philadelphia (Pembrolizumab, Intensity Modulated Radiation Therapy)

Active, not recruiting
Has Results
  • Head and Neck Cancer
  • Baltimore, Maryland
  • +2 more
Dec 7, 2022

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 26, 2022

Head and Neck Squamous Cell Carcinoma Trial in Baltimore (Pembrolizumab, IO102-103)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Baltimore, Maryland
    Johns Hopkins University
Aug 2, 2023

Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)

Not yet recruiting
  • Head and Neck Neoplasms
  • TransCon TLR7/8 Agonist
  • +2 more
  • (no location specified)
Aug 4, 2023

Cancer of Head and Neck, Head Neck Cancer, Tumors, Head and Neck Trial in Boston, Saint Louis, New York (biological, procedure,

Active, not recruiting
  • Cancer of Head and Neck
  • +5 more
  • MK-3475 (neoadjuvant)
  • +6 more
  • Boston, Massachusetts
  • +2 more
Dec 9, 2022

Advanced Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, MET-4, Placebo)

Not yet recruiting
  • Advanced Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Feb 22, 2023

Recurrent Head Neck Cancer, Metastatic Head Neck Cancer Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022